By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Merrimack Pharmaceuticals Inc. 

101 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-441-1000 Fax: 617-491-1386


Start Up


Dyax Corp.  Antibody phage display

Company News
Merrimack (MACK) Release: U.S. FDA Grants Priority Review For MM-398 New Drug Application 6/25/2015 6:30:00 AM
Merrimack (MACK) Announces The Addition Of John M. Dineen, Former CEO Of GE Healthcare, To Its Board Of Directors 6/16/2015 10:28:13 AM
Merrimack (MACK) Announces Expansion Of MM-398 (nal-IRI) Imaging Study To Patients With Metastatic Breast Cancer 6/12/2015 6:41:49 AM
Merrimack (MACK) Announces Data From An Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile For MM-398 In High-Grade Glioma 6/2/2015 6:16:46 AM
Battle of the Biotech Bands: Momenta (MNTA), PerkinElmer (PKI), Ironwood (IRWD) Will Try to Take Merrimack (MACK)'s Rock Crown 5/19/2015 9:17:02 AM
Merrimack (MACK) Announces Presentations At The 2015 ASCO Annual Meeting 5/14/2015 11:22:21 AM
Merrimack (MACK) Reports First Quarter 2015 Financial Results 5/8/2015 6:47:17 AM
Merrimack (MACK) Announces Initiation Of A Phase 2 Front-Line Clinical Trial Of MM-141 In Biomarker-Selected Patients With Metastatic Pancreatic Cancer 5/5/2015 6:15:37 AM
Baxter BioScience Corporation (BAX) And Merrimack (MACK) Announce Filing For European Approval Of MM-398, An Investigational Treatment For Post-Gemcitabine Metastatic Pancreatic Cancer 5/4/2015 11:29:20 AM
Merrimack (MACK) Announces Timing Of First Quarter 2015 Investor Conference Call And Presentation At Credit Suisse 2015 Antibody Conference 4/29/2015 11:09:48 AM